OlympiA adjuvant trial results show olaparib for BRCA 1/2 mutated and high-risk early breast cancer reduced recurrence risk by 42% Monet St Juste 23 september 2022
Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer Monet St Juste 23 september 2022
First results of the European AURORA study: towards a better understanding of the molecular changes driving metastatic breast cancer Monet St Juste 23 september 2022
First results of MA.32 trial: Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals Monet St Juste 23 september 2022